
|Videos|November 15, 2022
Chemoimmunotherapy in mNSCLC: Design and Outcomes of the POSEIDON Trial
Author(s)Edward B. Garon, MD, MS
A key opinion leader reviews the study design and efficacy and safety outcomes of the POSEIDON trial investigating durvalumab + tremelimumab + chemotherapy for treatment of mNSCLC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
5







































